INOZYME PHARMA, INC. Accrued Liabilities, Current
INOZYME PHARMA, INC. had Accrued Liabilities, Current of $12.74 million as of 2025-03-31, per its 10-Q filed 2025-05-14.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current › Accrued Liabilities, Current
us-gaap:AccruedLiabilitiesCurrent · last filed 2025-05-14
- 2025-03-31: Accrued Liabilities, Current $12.74M.
- 2024-12-31: Accrued Liabilities, Current $15.95M.
- 2024-09-30: Accrued Liabilities, Current $11.57M.
- 2024-06-30: Accrued Liabilities, Current $11.05M.
| Period end | Accrued Liabilities, Current |
|---|---|
| 2025-03-31 | $12.74M 10-Q · filed 2025-05-14 |
| 2024-12-31 | $15.95M 10-Q · filed 2025-05-14 |
| 2024-09-30 | $11.57M 10-Q · filed 2024-11-05 |
| 2024-06-30 | $11.05M 10-Q · filed 2024-08-06 |
| 2024-03-31 | $9.31M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $12.61M 10-K · filed 2025-03-10 |
| 2023-09-30 | $9.38M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $9.21M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $9.93M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $11.36M 10-K · filed 2024-03-12 |
| 2022-09-30 | $10.95M 10-Q · filed 2022-11-10 |
| 2022-06-30 | $8.46M 10-Q · filed 2022-08-15 |
| 2022-03-31 | $9.31M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $8.51M 10-K · filed 2023-03-22 |
| 2021-09-30 | $7.61M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $5.49M 10-Q · filed 2021-08-11 |
| 2021-03-31 | $4.45M 10-Q · filed 2021-05-12 |
| 2020-12-31 | $6.90M 10-K · filed 2022-03-15 |
| 2020-09-30 | $6.15M 10-Q · filed 2020-11-12 |
| 2020-06-30 | $5.33M 10-Q · filed 2020-09-03 |
| 2019-12-31 | $2.33M 10-K · filed 2021-03-25 |